Copy Link Print Information

Daratumumab

(Synonyms: Anti-Human CD38, Human Antibody; HuMax-CD38; JNJ-54767414)
13 Cited Publications
Avis client

Based on 13 publication(s) in Google Scholar

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté : 99.10%
  • CAS No.: 945721-28-8
  • Masse moléculaire:145.26 kDa
  • Stockage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Experimental Validation Results for Daratumumab
  • Daratumumab Chemical Structure
    Daratumumab Chemical Structure
CAS No.: 945721-28-8
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Daratumumab:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Pureté et documentation
  • Références
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Daratumumab

More
Customer Validation & Images
In Vivo Efficacy StudyCell Proliferation/Viability AssayBio/Physico-chemical AssayWB
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • WB
  • Cell Proliferation/Viability Assay
  • Bio/Physico-chemical Assay

Keywords

MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Flow cytometry analysis of Raji cells labelling CD38 with Daratumumab at 100nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

  • 1/16

    Daratumumab has a significant CDC effect on Raji cells in a dose-dependent manner. The EC50 for this effect is 96.2 and 98.6 ng/mL.

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Nat Biotechnol. 2025 Oct 17. [Abstract]

    Customer Validation
     A single mesodermal tumor was injected into mesodermal CAR-T cells, and the following treatments were administered: untreated group, daratumumab (0.5 or 10 μg/ml) treatment group, or IgG isotype control antibody (10 μg/ml IgG) treatment group. The change in T cell area over time was quantitatively analyzed.

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]

    Customer Validation
     ADCC in H929 cells caused by various concentration of Dara (Daratumumab, 1h treatment and 4h NK cell co-culture).

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]

    Customer Validation
     Compared with vehicle control, Dara (Daratumumab, i.p. 8 mg/kg per mouse weekly for 3w) cause significantly reduction of xenograft tumors weight and tumor growth.

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]

    Customer Validation
     Inhibitor of ALDH1A 673 A remarkably reduce the protein level of CD38, ALDH1A1 and RAR, and RA complement significantly restore the protein level of CD38 and RAR. Dara (Daratumumab, i.p. 8 mg/kg per mouse weekly for 3w).

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. [Abstract]

    Customer Validation
     ADCC capability of INBRX-109 was evaluated in the Promega Jurkat CD16a (V158) ADCC reporter assay using DR5-transfected ExpiCHO-S cells as targets and untransfected cells as negative controls. Daratumumab (5.5 h), the target of which is expressed on Jurkat cells, serves as a positive control.

  • 1/16

    Daratumumab purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. [Abstract]

    Customer Validation
     The ability of INBRX-109 to bind the complement component C1q contained within normal human serum was measured by ELISA. Daratumumab (5.5 h) is used as a positive control.

  • Daratumumab Chemical Structure
    1/16
  • Daratumumab
  • Flow cytometry analysis of Raji cells labelling CD38 with Daratumumab at 100nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
  • Daratumumab has a significant CDC effect on Raji cells in a dose-dependent manner. The EC50 for this effect is 96.2 and 98.6 ng/mL.